Processa Pharmaceuticals Provides An Interim Analysis From Its Ongoing Phase 1B Trial Of Next Generation Capecitabine For Gastrointestinal Cancer; Interim Analysis Suggests Processa's Chemotherapy Treatment Could Improve Safety And Efficacy
Portfolio Pulse from Benzinga Newsdesk
Processa Pharmaceuticals has provided an interim analysis from its ongoing Phase 1B trial of next-generation Capecitabine for gastrointestinal cancer. The interim analysis suggests that Processa's chemotherapy treatment could improve safety and efficacy.
August 17, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Processa Pharmaceuticals' ongoing Phase 1B trial of next-generation Capecitabine for gastrointestinal cancer shows promising interim results, potentially improving safety and efficacy of the treatment.
The interim analysis of Processa Pharmaceuticals' ongoing Phase 1B trial suggests that their next-generation Capecitabine could improve the safety and efficacy of gastrointestinal cancer treatment. This positive news could potentially increase investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100